Kurs Vortag | 76,37 |
Öffnen | 76,38 |
Gebot | 77,02 x 50000 |
Briefkurs | 77,08 x 50000 |
Tagesspanne | 76,38 - 76,54 |
52-Wochen-Spanne | 52,23 - 84,73 |
Volumen | |
Durchschn. Volumen | 1.669 |
Marktkap. | 96,722B |
Beta (5 J., monatlich) | 0,43 |
Kurs-Gewinn-Verhältnis (roll. Hochrechn.) | 31,63 |
EPS (roll. Hochrechn.) | 2,42 |
Gewinndatum | 02. Feb. 2023 |
Erwartete Dividende & Rendite | 2,75 (3,58%) |
Ex-Dividendendatum | 14. Dez. 2022 |
1-Jahres-Kursziel | N/A |
NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences While Jesse Garcia was growing up in Chicago's inner city, his parents didn't immediately turn to a doctor when someone in the family got sick. "We relied on traditional Latino ...
NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences Since the beginning of the COVID-19 pandemic, Gilead's first-in-class antiviral was made available to more than 11 million patients globally- over 65% of whom live in low-and lower-middle-income ...
In the spring of 2018, North Carolina native Stephanie Walker went to her first breast cancer conference and had a revelation that she refers to as her "coming-out party." She learned she had metastatic breast cancer three years earlier and although she was a retired hospice nurse, she faced the disease without any guidance from others who shared her experience.